A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes.
Lynda Stranix-ChibandaChenchen YuMargaret Brewinski IsaacsMary AllenJessica AndriesenStephen R WalshPublished in: BMC infectious diseases (2021)
Although there is considerable heterogeneity amongst the different vaccine trials, there appears to be no obvious indication of increased risk of adverse pregnancy or birth outcomes in these early phase HIV-1 vaccine studies. More complete data on pregnancy outcomes should be collected in early phase HIV-1 vaccine clinical trials to better inform subsequent efficacy trials.
Keyphrases
- pregnancy outcomes
- antiretroviral therapy
- hiv positive
- hiv infected
- pregnant women
- human immunodeficiency virus
- hiv testing
- hepatitis c virus
- hiv aids
- clinical trial
- preterm birth
- men who have sex with men
- cardiovascular disease
- south africa
- gestational age
- emergency department
- data analysis
- skeletal muscle
- insulin resistance
- electronic health record
- big data
- case control